Sanofi reorganizing the four-price flu vaccine was approved in the European Union, the domestic is expected to be introduced as soon as possible

The European Commission has approved Sanofi Pasteur's recombination of the four-price flu vaccine to be available in 31 European countries for influenza prevention in adults aged 18 and over.
is the world's first and only recombined four-price flu vaccine to be approved.
the vaccine approved in Europe called Supertek? Before it was approved in the United States, the product was named Flublok Quadrivalent?
the EU's approval was based on data from two Phase III. randomized controlled trials, which included more than 10,000 subjects, and confirmed the safety, immunogenicity and effectiveness of a new generation of recombined four-price influenza vaccines.
compared to influenza vaccines produced in conventional chicken embryos, recombinant tetr flu vaccines avoid the risk of reduced strain matching and reduced vaccine effectiveness due to adaptive mutations in strains during production.
, the recombinant four-price flu vaccine contains three times the dose of antigen.
compared to the standard dose of the four-price flu vaccine, the recombination of the four-price flu vaccine can further reduce the risk of influenza by 30% in adults aged 50 and over.
, the effectiveness of the recombined four-price influenza vaccine in the elderly population in Hong Kong has been strongly confirmed in clinical studies.
A study by Benjamin John Cowling, head of the Department of Epidemiology and Statistics at the School of Public Health of the University of Hong Kong, said: "By comparing the immunogenicity of the recombinant four-price influenza vaccine with the standard four-price influenza vaccine in the elderly population in Hong Kong, the recombinant four-price influenza vaccine is more likely to improve antibody titration after vaccination than the standard dose of the four-price influenza vaccine, especially for the H3N2 subtype virus, the advantages of immunogenicity are more obvious."
, general manager of Sanofi Pasteur China, said: "At present, we are maintaining close communication and cooperation with various agencies, and strive to introduce a recombined four-price influenza vaccine as soon as possible."
" in the winter when the new crown outbreak is likely to be high, there may be a risk of a superimposed flu and new crown respiratory infections.
currently, influenza vaccination is still the most effective means of preventing influenza, because the early symptoms of neocoopia are similar to influenza, so influenza vaccination can also reduce the difficulty of identifying the two diseases in the event of infection to some extent.
professor Zeng Guang, a former chief epidemiologist at the CDC, said: "Compared to the World Health Organization's estimate of an annual influenza incidence rate of 5%-10%8 among adults globally, the overall incidence of influenza in China is still underestimated."
under the new normal of prevention and control of the new crown pneumonia epidemic, special attention should be paid to and strengthened influenza prevention and control, beware of potential 'new crown-flu' double attack.
" Secrets Source: Euro Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here